Free tool
Cell therapy stocks
We cover 3 companies grouped under the Cell therapy theme. The median market value in the group is $1.00B. Across the group, the median move over the past trading day is −0.59%. Price change over the past year runs from +59.7% to +517.6% across the middle 80 percent of the group, with a median of +116.7%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
3 of 86 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| BLFS | BioLife Solutions, Inc. | $1.82B | Small cap | +45.50% |
| IMMX | Immix Biopharma, Inc. | $1.00B | Small cap | +617.86% |
| CABA | Cabaletta Bio, Inc. | $545.94M | Small cap | +116.67% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.